Dfb Pharmaceuticals, Inc.

Dfb Technology Holdings, LLC

Smith + Nephew

Epitech Sa

Modex Therapeutiques, S.a.

Sinclair Pharmaceuticals Limited

Thomas Hunziker

Christopher Rinsch

Eric Rolland

Beatrice Mis

Alain Limat

Beatrice Chevallay

E Edward Baetge

Eric Holland

Vincent Ronfard

A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vile, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF&#x3b2;, angiopoietin, EGF, IL-I&#x3b2;, TGF&#x3b1;, and TNF&#x3b1;, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second vial.

Methods and compositions for tissue regeneration

A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF&#x3b2;, angiopoietin, EGF, IL-I&#x3b2;, IL-6, IL-8, TGF&#x3b1;, and TNF&#x3b1;, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.

Disclosed is a method of treating a wound comprising applying a composition to a wound site on a patient in need of wound treatment, wherein the composition comprises mitotically inactive allogeneic cells that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF&#x3b2;, angiopoietin, EGF, IL-I&#x3b2;, IL-6 IL-8, TGF&#x3b1;, and TNF&#x3b1;, and wherein the cells are keratinocytes or fibroblasts, or mixtures thereof.

Disclosed is a composition comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF&#x3b2;, angiopoietin, EGF, IL-ID, IL-, IL-, TGF&#x3b1;, and TNF&#x3b1; and an extracellular matrix comprising alginate, wherein the cells are allogeneic and mitotically inactive.

Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.

The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.

The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.

Keratinocyte culture and uses thereof

The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated from blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.

Keratinocyte cultures and uses thereof

The present invention provides the use and composition of matter of angiogenic or other growth factors expressed by combining various types and stages of differentiation of allogeneic human cell strains or lines in unencapsulated pastes (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) to be temporarily applied to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.

Cell paste comprising keratinocytes and fibroblasts

The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagenic or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated from blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.

Growing community of inventors

Oberhofen, Switzerland

Thomas Hunziker